CN110461841A - 一种具有csf1r抑制活性的氮杂芳基衍生物、其制备方法和应用 - Google Patents

一种具有csf1r抑制活性的氮杂芳基衍生物、其制备方法和应用 Download PDF

Info

Publication number
CN110461841A
CN110461841A CN201880021734.4A CN201880021734A CN110461841A CN 110461841 A CN110461841 A CN 110461841A CN 201880021734 A CN201880021734 A CN 201880021734A CN 110461841 A CN110461841 A CN 110461841A
Authority
CN
China
Prior art keywords
deuterium
substituted
radical
alkyl radical
cycloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201880021734.4A
Other languages
English (en)
Other versions
CN110461841B (zh
Inventor
张鸣鸣
赵保卫
喻红平
陈椎
徐耀昌
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbisko Therapeutics Co Ltd
Original Assignee
Abbisko Therapeutics Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbisko Therapeutics Co Ltd filed Critical Abbisko Therapeutics Co Ltd
Publication of CN110461841A publication Critical patent/CN110461841A/zh
Application granted granted Critical
Publication of CN110461841B publication Critical patent/CN110461841B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Abstract

本发明提供了一种具有CSF1R抑制活性的氮杂芳基衍生物、其制备方法和应用。本发明系列化合物具有如下式(Ⅰ)结构，各取代基的定义如说明书和权利要求书所述。本发明系列化合物可广泛应用于制备治疗癌症、肿瘤、自身免疫性疾病、代谢性疾病或转移性疾病的药物，特别是治疗卵巢癌、胰腺癌、前列腺癌、乳腺癌、宫颈癌、成胶质细胞瘤、多发性骨髓瘤、代谢性疾病、神经变性疾病、原发性肿瘤位点的转移或骨转移性癌症的药物，有望开发成新一代CSF1R抑制剂药物。

Description

PCT国内申请，说明书已公开。

Claims (25)

  1. PCT国内申请，权利要求书已公开。
CN201880021734.4A 2017-06-19 2018-06-13 一种具有csf1r抑制活性的氮杂芳基衍生物、其制备方法和应用 Active CN110461841B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2017104647777 2017-06-19
CN201710464777 2017-06-19
PCT/CN2018/091045 WO2018233527A1 (zh) 2017-06-19 2018-06-13 一种具有csf1r抑制活性的氮杂芳基衍生物、其制备方法和应用

Publications (2)

Publication Number Publication Date
CN110461841A true CN110461841A (zh) 2019-11-15
CN110461841B CN110461841B (zh) 2020-09-15

Family

ID=64736847

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880021734.4A Active CN110461841B (zh) 2017-06-19 2018-06-13 一种具有csf1r抑制活性的氮杂芳基衍生物、其制备方法和应用

Country Status (5)

Country Link
US (1) US11180495B2 (zh)
EP (1) EP3643715A4 (zh)
JP (1) JP7131837B2 (zh)
CN (1) CN110461841B (zh)
WO (1) WO2018233527A1 (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115960106A (zh) * 2022-11-03 2023-04-14 中国药科大学 线粒体rna聚合酶抑制剂及其衍生物、药物组合物和医药用途

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3632907B1 (en) * 2017-05-24 2024-02-28 Abbisko Therapeutics Co., Ltd. N-(azaaryl)cyclolactam-1-carboxamide derivative, preparation method therefor, and use thereof
CA3182595A1 (en) * 2020-06-17 2021-12-23 Mingming Zhang Immunosuppressant, and preparation method therefor and use thereof
JP2023543006A (ja) * 2020-09-25 2023-10-12 成都嘉葆薬銀医薬科技有限公司 １Ｈ－ピロロ［２，３－ｃ］ピリジン系化合物及びその使用
WO2023179793A1 (zh) * 2022-03-25 2023-09-28 成都嘉葆药银医药科技有限公司 一种1H-吡咯并[2,3-c]吡啶类化合物的晶型及其制备方法
CN114853672B (zh) * 2022-05-12 2023-06-23 中国人民解放军北部战区总医院 作为CDKs抑制剂的他克林衍生物及其应用
CN115232147B (zh) * 2022-08-09 2023-10-13 南方科技大学 一种作为HIF-2α激动剂的杂环衍生物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA93679C2 (en) * 2005-05-17 2011-03-10 Плексикон, Инк. Compounds modulating c-kit and c-fms activity and uses therefor
MX2007014377A (es) 2005-05-17 2008-02-06 Plexxikon Inc Inhibidores de proteina cinasa de derivados de pirrol (2,3-b) piridina.
WO2008063888A2 (en) 2006-11-22 2008-05-29 Plexxikon, Inc. Compounds modulating c-fms and/or c-kit activity and uses therefor
DE102011009961A1 (de) * 2011-02-01 2012-08-02 Merck Patent Gmbh 7-Azaindolderivate
TWI520962B (zh) 2012-06-29 2016-02-11 As the c-Met tyrosine kinase inhibitors novel fused pyridine derivatives
US9193719B2 (en) * 2013-03-15 2015-11-24 Deciphera Pharmaceuticals, Llc 1,2,4-triazol-5-ones and analogs exhibiting anti-cancer and anti-proliferative activities
BR112015022288B1 (pt) * 2013-03-15 2022-06-21 Deciphera Pharmaceuticals Llc 2-aminopirimidin-6-onas e análogos exibindo atividades anticâncer e antiproliferativas, seus usos, e composição farmacêutica
TW201722957A (zh) 2015-09-15 2017-07-01 葛蘭素史克智慧財產（第二）有限公司 化學化合物
CN110467615A (zh) * 2018-05-10 2019-11-19 四川科伦博泰生物医药股份有限公司 吡咯并嘧啶类化合物、包含其的药物组合物及其制备方法和用途

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115960106A (zh) * 2022-11-03 2023-04-14 中国药科大学 线粒体rna聚合酶抑制剂及其衍生物、药物组合物和医药用途
CN115960106B (zh) * 2022-11-03 2024-03-26 中国药科大学 线粒体rna聚合酶抑制剂及其衍生物、药物组合物和医药用途

Also Published As

Publication number Publication date
WO2018233527A1 (zh) 2018-12-27
EP3643715A4 (en) 2020-10-28
US11180495B2 (en) 2021-11-23
JP7131837B2 (ja) 2022-09-06
EP3643715A1 (en) 2020-04-29
CN110461841B (zh) 2020-09-15
US20200140431A1 (en) 2020-05-07
JP2020524159A (ja) 2020-08-13

Similar Documents

Publication Publication Date Title
CN110461841B (zh) 一种具有csf1r抑制活性的氮杂芳基衍生物、其制备方法和应用
TWI757256B (zh) 轉染過程重排之抑制劑
TWI716686B (zh) N-(氮雜芳基)環內醯胺-1-甲醯胺衍生物及其製備方法和應用
KR101469334B1 (ko) Ｎ-9-치환된 퓨린 화합물, 조성물 및 사용 방법
WO2016127074A1 (en) 2-(pyridin-3-yl)-pyrimidine derivatives as ret inhibitors
CN110546145B (zh) 一种氮杂芳基衍生物、其制备方法和在药学上的应用
CN110461849B (zh) 一种csf1r抑制剂及其制备方法和应用
CN110691775B (zh) 一种具有fgfr4抑制活性的醛基吡啶衍生物、其制备方法和应用
CN111868058A (zh) 一种fgfr抑制剂、其制备方法和在药学上的应用
CN113366008B (zh) 一种cd73抑制剂，其制备方法和应用
JP7349750B2 (ja) キナーゼ阻害活性を有する芳香族複素環式化合物
CN111936493A (zh) 一种高选择性FGFRi抑制剂及其制备方法和应用
CN112119064A (zh) Fgfr抑制剂、其制备方法和应用
EP3697786A1 (en) Substituted pyrrolopyridines as inhibitors of activin receptor-like kinase
CN111763217B (zh) 一类噻吩并氮杂环类化合物、制备方法和用途
CN114369097B (zh) 杂芳环类AhR抑制剂
CN115703799A (zh) 氮杂芳基化合物、其制备方法及应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant